Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395017 · ClinicalTrials.gov registry record · Phase 2
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
NCT01395017 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 202 participants.
The verdict
NCT01395017, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.
Interventions
- DRUG Placebo
- DRUG dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395017
The ClinicalTrials.gov registry entry for NCT01395017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01395017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395017 about?
NCT01395017 is a clinical study titled "Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer". The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.
What is the current status of trial NCT01395017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2011-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01395017?
The interventions under investigation include: Placebo (DRUG), dasatinib (DRUG).
Who is sponsoring clinical trial NCT01395017?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.